Optimistic Buy Rating for Revolution Medicines' RMC-6236 Amid Favorable Clinical Data and Strategic Management Decisions
New York Community Analyst Ratings
Embecta Analyst Ratings
Nevro Analyst Ratings
IRhythm Technologies Analyst Ratings
Integra Lifesciences Analyst Ratings
Treace Medical Concepts Analyst Ratings
Humacyte Analyst Ratings
RxSight Analyst Ratings
SI-BONE Analyst Ratings
Glaukos Analyst Ratings
Vericel Analyst Ratings
Alphatec Holdings Analyst Ratings
Chart Industries Analyst Ratings
TD Cowen Adjusts Credo Technology Group Holding Price Target to $40 From $35, Maintains Buy Rating
Evercore ISI Raises Meritage Homes Price Target to $221 From $219, Maintains Outperform Rating
Credo Technology Group Analyst Ratings
Stephens Adjusts Bank7 Price Target to $39 From $31, Maintains Equal Weight Rating
StepStone Group Analyst Ratings
UBS Adjusts Price Target on Verra Mobility to $34.50 From $27, Maintains Buy Rating